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Abstract
Surfactant protein D (SP-D) is a member of the family of collagenous host defense lectins, designated collectins. There is
increasing evidence that SP-D, like SP-A, is an important component of the innate immune response to microbial challenge,
and that it may participate in other aspects of immune and inflammatory regulation within the lung. SP-D binds to
glycoconjugates and/or lipid moieties expressed by a wide variety of microorganisms and certain other organic particles, in
vitro. Although binding may facilitate microbial clearance through aggregation or other direct effects on the organism, SP-D
also has the capacity to modulate leukocyte function, and in some circumstances, to enhance their killing of
microorganisms. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Surfactant protein D (SP-D) was initially described
as one of several collagenous glycoproteins secreted
by freshly isolated rat type II cells [1]. It was subse-
quently identi¢ed in bronchoalveolar lavage (BAL)
and in association with crude surfactant [2]. Protein
and cDNA sequencing of SP-D led to the identi¢ca-
tion of a C-type lectin domain [3^5], and prompted
studies that demonstrated lectin activity and saccha-
ride-mediated binding to surfactant in vitro [6]. SP-D
is now recognized as a member of a family of collag-
enous carbohydrate binding proteins (collagenous C-
type lectins), commonly known as collectins [7,8].
These include SP-A, serum mannose binding protein
and two bovine serum lectins, conglutinin and CL-
43.
Kuan and coworkers demonstrated that SP-D
binds to Gram-negative bacteria via its lectin do-
main, and that SP-D is a potent agglutinin of some
bacterial strains [9]. Numerous subsequent studies
have con¢rmed that SP-D shows speci¢c interactions
with various microorganisms and leukocytes in vitro.
Recent observations suggest that SP-D is part of a
more generalized response of the lung to acute lung
injury, and that it may modulate local in£ammatory/
immune responses, as well as participate in the rec-
ognition or clearance of other complex organic ma-
terials, such as dust mite allergens [10^13].
2. Molecular structure
SP-D (43 kDa, reduced) is predominantly as-
sembled as dodecamers consisting of four homotri-
meric subunits (4U3 = 12 chains) with relatively long
triple helical arms [14] (Figs. 1 and 2). Each trimeric
subunit contains four major domains: a short cys-
teine-containing NH2-terminal crosslinking domain
(N), a triple helical collagen domain of variable
length, a trimeric coiled-coil linking domain or
neck (L), and a carboxy-terminal, C-type lectin car-
bohydrate recognition domain (CRD). Interactions
between the amino-terminal domains of SP-D sub-
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units are stabilized by interchain disul¢de bonds
[14,15]. In contrast to SP-A, the collagen domain
of SP-D contains hydroxylysine and hydroxylysyl
glycosides [2] and lacks detectable blood group de-
terminants (W. Longmore, unpublished data). Other
possible modi¢cations, including sulfation, acetyla-
tion, O-glycosylation at sites other than hydroxyly-
sine, have not been speci¢cally excluded.
Although natural and recombinant rat SP-Ds are
almost exclusively assembled as dodecamers, prepa-
rations of natural human and bovine SP-D can also
include trimers [4,16,17]. It is unclear whether the
accumulation of these incompletely assembled mole-
cules re£ects di¡erences in the e⁄ciency of intracel-
lular multimerization or in the stability of secreted
dodecamers. Mason and coworkers have also identi-
¢ed a novel SP-D variant that elutes much later from
gel ¢ltration columns than dodecamers [18]. It is
present in the lavage from some but not all normal
individuals and proteinosis patients. The constituent
chains migrate more slowly than the major form of
SP-D on SDS-PAGE and show evidence of threo-
nine-linked glycosylation of the pepsin-resistant col-
lagen domain (R. Mason, personal communication).
SP-D dodecamers can self-associate at their ami-
no-termini to form highly ordered, multimers with
complex arrays of up to 32 (or more) trimeric
CRDs [14,17,19] (Fig. 3). Natural SP-D from human
alveolar proteinosis and bovine lavage and recombi-
nant human SP-D contain a high proportion of these
multimers. They are not dissociated by EDTA or
competing sugars, and are crosslinked by disul¢de
and non-disul¢de bonds. SP-D multimers show high-
er apparent binding a⁄nity to a variety of ligands
and are considerably more potent on a molar or
weight basis in mediating microbial aggregation
and aggregation-dependent interactions with leuko-
cytes [17,20].
3. Biochemical properties
3.1. Charge
SP-D is secreted as several distinct basic isoforms
(pI 5^9) that can be resolved by 2-D isoelectric fo-
cusing/SDS-PAGE [1]. Because the predicted pI of
the CRD is 6 5, the charge is largely determined
by the collagen domain, which is very basic
(pIW10). Resolution of newly synthesized or natural
rat SP-D by DEAE chromatography under non-de-
naturing conditions also partially resolves species of
di¡erent monomer size attributable to di¡erences in
terminal sialylation [1].
3.2. Binding of divalent cations
The saccharide binding activity of SP-D is abol-
ished with 2 mM EDTA (or EGTA), and can be
restored following readdition of excess calcium [6].
Neoglycoprotein binding assays are consistent with
the presence of at least one high a⁄nity binding
Fig. 2. Molecular organization of SP-D. The predominant mo-
lecular form of SP-D is a dodecamer consisting of four trimeric
subunits.
Fig. 3. Alternative molecular forms of SP-D. Trimeric CRDs
and SP-D multimers are compared with SP-D dodecamers. The
minimum structure required for high a⁄nity binding is the tri-
meric CRD.
Fig. 1. Domain structure of SP-D. The amino-terminal, collage-
nous, L peptide, and carbohydrate recognition domains (CRD)
are identi¢ed. The Asn-linked oligosaccharide in SP-D is lo-
cated in the collagen domain.
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site (1036 M) [6]. Although SP-D is fully soluble in
saline at neutral pH and precipitates in low salt
bu¡ers, it can reversibly precipitate in the presence
of calcium at physiologic pH and ionic strength. This
results from lectin-dependent aggregation, presum-
ably mediated by binding of the CRD to N- or O-
linked glycoconjugates within the collagen domain.
3.3. Disul¢de crosslinks
By analogy with other collectins, crosslinking of
the cysteines of SP-D (Cys261-Cys353 and Cys331-
Cys345) is predicted. A variety of observations sug-
gest the intrachain bonds are required for calcium-
dependent saccharide binding, and confer resistance
to thermal denaturation or proteolytic degradation.
Interchain disul¢de bonds are required for the forma-
tion of stable trimeric subunits and higher order
oligomers. Low concentrations of sulfhydryl reduc-
ing agents can liberate trimeric subunits from collec-
tin molecules, sometimes with partial preservation of
intratrimeric disul¢de bonds depending on the con-
centration of reducing agent and incubation temper-
ature [14].
4. Interactions with carbohydrate and lipid ligands
4.1. Carbohydrate binding
Puri¢ed natural rat, human, and bovine SP-D, as
well as recombinant rat and human molecules, pref-
erentially recognize the K-anomeric con¢guration of
nonreducing glucopyranosides [6]. The order of pref-
erence of human SP-D in solid phase competition
assays using maltosyl-BSA as the ligand is approxi-
mately: maltose, (inositol)s glucose, mannose, fuco-
ses galactose, lactose, glucosaminesN-acetylglucos-
amine. This binding speci¢city is consistent with
known interactions of SP-D with the glucose-con-
taining core oligosaccharides of LPS, and with the
mannose-rich N-linked oligosaccharides of the he-
magglutinin of in£uenza A and the gpA of Pneumo-
cystis carinii (see below).
4.2. Lipid binding
Puri¢ed SP-D shows high a⁄nity binding to phos-
phatidylinositol (PI) resolved on thin-layer chroma-
tography (TLC) plates or presented in liposomes [21^
23]. PI is also the major surfactant-associated ligand
of SP-D. In addition, SP-D binds to glucosyl-ceram-
ide when displayed on TLC plates [24]. The interac-
tions of SP-D with PI and glucosyl-ceramide are cal-
cium-dependent and inhibited by competing sugars
[22]. Surface balance studies have demonstrated
only limited interactions of recombinant rat SP-D
with monomolecular layers of phospholipids [25].
In these experiments, there was no detectable phos-
pholipid head-group preference and interactions of
SP-D with the lipid were attributed to hydrophobic
interactions. The reason for the apparent discrepancy
with previous studies is unknown, but could re£ect
the comparatively low sensitivity of the physical
measurements.
4.3. Structural requirements for ligand binding
As indicated in Section 1 the primary sequence of
the carboxy-terminal domains SP-D contains charac-
teristic elements of the mannose-type C-type lectin
motif [3^5]. Biochemical and molecular studies have
de¢nitively established that these domains are pri-
marily responsible for the carbohydrate binding ac-
tivity. For example, site-directed mutagenesis of con-
served residues of the mannose-type saccharide
binding site (Glu321 to Gln and Asn323 to Asp) re-
versed the relative carbohydrate binding speci¢city
from maltose, glucoses galactose to galactosesmal-
tose, glucose [26]. Phospholipid binding by SP-D in-
volves interactions with the CRD but also requires
the L peptide [26]. However, it is not known whether
the L peptide directly participates in binding in the
intact protein, or whether hydrophobic interactions
between the L peptide and CRD are required to
maintain a speci¢c conformation or spatial distribu-
tion of the CRDs [27].
The linking peptide in conjunction with the CRD
domain (L+CRD) can form trimers, and interactions
between hydrophobic sequences on L and the CRD
determine the spatial distribution of the three CRDs,
thereby generating a single, trimeric, high a⁄nity lig-
and binding site [27]. The trimeric CRDs show the
same saccharide inhibition pro¢le as natural human
SP-D [28]. However, the capacity for bridging inter-
actions between spatially separated ligands depends
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on an appropriate oligomerization of trimeric sub-
units, resulting in a characteristic spatial distribution
of the trimeric CRDs. A single-arm mutant, RrSP-D-
Ser15/20, and bacterially expressed trimeric
L+CRDs, do not cause signi¢cant bacterial aggrega-
tion and viral precipitation [15]. In addition, trimeric
CRDs and single-arm forms of the protein can func-
tion as competitive inhibitors of SP-D-mediated mi-
crobial aggregation. Thus, trimeric SP-D CRDs ap-
pear to be functionally univalent with regard to their
capacity to participate in bridging interactions be-
tween large particulate ligands.
5. Interactions of lung SP-D with microbial ligands
The lining material of the alveoli and distal air-
ways is ideally positioned to participate in the neu-
tralization and clearance of inhaled microorganisms.
Because the large serum collectins are presumed to
be present at very low concentrations in the extra-
vascular space in uninjured tissues, SP-A and SP-D
probably constitute the major collectin defenses of
the lung.
5.1. Viral glycoconjugates
The interactions of lung collectins with in£uenza A
viruses (IAVs) have been extensively characterized.
IAV attaches to and infects cells by binding through
its hemagglutinin to sialic acid-bearing components
on the cell surface. The collectins, including SP-D,
are potent inhibitors of HA mediated agglutination,
and the levels of SP-D in lavage £uids are su⁄cient
to account for a signi¢cant fraction of the total HA
inhibitory activity of the £uids [29].
HA inhibition by SP-D involves the binding of SP-
D through its CRD to glycoconjugates expressed
near the sialic acid binding site on the hemagglutinin
(or neuraminidase) of speci¢c strains of IAV [20].
Higher degrees of valency or multimerization among
the various SP-D preparations are associated with
increased HA inhibitory activity [17]. At least with
some strains of IAV there is also binding to glyco-
conjugates associated with the viral neuraminidase,
and it has been suggested that collectin binding to
the NA can sterically interfere with HA activity [30].
As discussed in greater detail below, an important
aspect of the interaction of collectins with IAV is
their ability to cause viral aggregation, and to en-
hance other aggregation-dependent activities [17,20].
Among the collectins, SP-D is the most potent at
aggregating IAV particles, and multimers of dodeca-
mers are much more potent than dodecamers.
SP-D is a potent inhibitor of IAV infectivity as
measured by the egg inoculation assay, and more
potent at inhibiting IAV infectivity than SP-A (or
MBL) [17]. Recent studies have also shown that the
susceptibility of various IAV strains to neutralization
by SP-D in vitro is inversely correlated with pulmo-
nary viral replication in mice following nasal inocu-
lation [31] and directly correlates with speci¢c di¡er-
ences in the number of glycoconjugates expressed on
the hemagglutinin. Inoculation of mice in the pres-
ence of mannan, a saccharide competitor of SP-D
binding to IAV, also increases viral replication in
mice consistent with involvement of a C-type lectin.
5.2. Bacterial glycoconjugates
SP-D binds to glycoconjugates expressed by a va-
riety of Gram-negative bacteria including speci¢c
strains of such important pulmonary pathogens as
Klebsiella pneumoniae, Pseudomonas aeruginosa,
Hemophilus in£uenzae, and Escherichia coli. Core
sugars of LPS (glucose and/or heptose) have been
identi¢ed have been identi¢ed as major ligands for
rat or human SP-D on E. coli and Salmonella min-
nesota [9]. SP-D also binds to isolated LPS from a
variety of other Gram-negative bacteria including
K. pneumoniae and P. aeruginosa [9,28,32]. Puri¢ed
natural or recombinant dodecamers are potent
agglutinins for bacterial strains expressing O-anti-
gen-de¢cient LPS molecules (e.g. rough strains of
E. coli), and cause gross aggregation and precipita-
tion of suspended organisms. In contrast to SP-A,
SP-D binding to LPS and its e¡ects on bacterial
aggregation are blocked by EDTA, competing sug-
ars, LPS, and rough mutant forms of LPS, but not
by lipid A [9]. Although SP-D also binds poorly to
most smooth (O-antigen-containing) LPS on lectin
blots, SP-D can still bind to O-antigen-expressing
bacteria, as evidenced by speci¢c labeling and micro-
aggregation in immuno£uorescence assays [9]. We
have observed that growth conditions (e.g. aeration)
can markedly in£uence the aggregation of speci¢c
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Gram-negative bacterial strains by SP-D, and that
the extent of macroscopic aggregation inversely cor-
relates with the size and complexity of the terminal
O-antigen. Interestingly, SP-D was identi¢ed as the
major E. coli binding protein in cell-free rat BAL [9].
In collaborative studies with Dr. Itzhak Ofek, we
observed interactions of SP-D with speci¢c strains of
K. pneumoniae distinct from those recognized by SP-
A. Speci¢cally, SP-D showed lectin-dependent agglu-
tination of two unencapsulated variants of K50 and
K21a, and at least one weakly encapsulated strain
[32]. The binding of SP-D to the isolated Klebsiella
LPS was inhibited by EDTA, competing sugars, and
LPS from other Gram-negative bacteria, but not by
capsular polysaccharides. Although encapsulated
strains can apparently bind SP-D, they do not under-
go macroscopic aggregation. These observations sug-
gest that SP-D does not recognize the capsular poly-
saccharides of K. pneumoniae, and that the presence
of a well-formed capsule limits interactions of SP-D
with underlying LPS molecules.
5.3. Fungal glycoconjugates
Recent studies have demonstrated speci¢c lectin-
dependent interactions of both rat and human SP-
D with gpA, a mannose- and glucose-rich glycopro-
tein expressed on cysts and trophozoites of Pneumo-
cystis carinii (PC) [33^35]. SP-D is associated with
PC in vivo, and are present on the surface of freshly
isolated organisms. Clusters of organisms in bron-
choalveolar lavage can be partially disaggregated
with EDTA or competing sugars, and ‘stripped’ or-
ganisms can be agglutinated by puri¢ed SP-D, sug-
gesting that SP-D contributes to the clustering of
cysts observed in vivo. Interestingly, the production
and accumulation of SP-D is increased in rats and
immunosuppressed patients with Pneumocystis pneu-
monia [33].
Recombinant rat and human SP-D bind to patho-
genic unencapsulated, but not the capsulated, forms
of Cryptococcus neoformans through a lectin-depend-
ent mechanism [36]. Although the unencapsulated
organisms are readily agglutinated by SP-D, there
is no signi¢cant aggregation by SP-A. More recently
human proteinosis SP-D was shown to bind to As-
pergillus fumigatus conidia in a calcium- and carbo-
hydrate-dependent fashion consistent with binding of
the CRD to cell wall glycoconjugates [37]. SP-D e⁄-
ciently agglutinated the conidia. These interactions
likely involve binding to glucans and/or glycopro-
teins associated with the fungal cell wall.
6. Interactions of SP-D with phagocytes
There are at least three mechanisms by which SP-
D can modify the activities of pulmonary leukocytes.
These include: opsonization or other e¡ects mediated
by the speci¢c interactions of the leukocyte with SP-
D-coated organisms, direct e¡ects of SP-D on phago-
cyte function, and SP-D-mediated alterations in
particle presentation secondary to aggregation. The
¢rst two mechanisms require binding sites for SP-D
on the leukocyte cell surface, while the latter could
use pre-existing leukocyte ‘receptors’ (ligands) for
microorganisms. Particle opsonization may theoreti-
cally involve: protein receptor-mediated binding of
the SP-D to the leukocyte, collectin-mediated bridg-
ing interactions between glycoconjugates expressed
on the particle and host defense cell, and/or binding
of the host cell to glycoconjugates expressed on SP-
D. It seems probable that all of these mechanisms
may be operative, alone or in combination, in spe-
ci¢c microbial-phagocyte interactions.
6.1. SP-D receptors
SP-D does not interact with C1q receptors [38].
However, SP-D has been shown to be recognized
by one or more receptors or binding proteins on
alveolar macrophages [38]. This binding does not
appear to involve the lectin activity of SP-D since
binding was performed in the presence of EDTA.
It remains unclear to what extent the binding moi-
eties may be related to the non-C1qR SP-A recep-
tors.
Holmskov and coworkers have recently reported
the isolation of an SP-D binding protein (GP-340)
from human proteinosis lavage [39]. The protein,
which is a member of the scavenger receptor super-
family, speci¢cally binds to the L peptide region of
SP-D. Antibodies to the protein to the protein show
selective binding to alveolar macrophages. The GP-
340 gene has been sequenced, and is closely related to
a putative tumor-suppressor gene, DMBT1 [40].
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6.2. Glycoconjugate ‘receptors’ on leukocytes
SP-D can interact with leukocytes via lectin-de-
pendent binding to cell surface glycoconjugates
[10,41]. Biotinylated SP-D shows signi¢cant speci¢c
maltose-dependent binding to rat lung macrophages
in frozen tissue sections [41]. Binding of FITC-la-
beled SP-D to freshly isolated aldehyde-¢xed rat al-
veolar macrophages is eliminated after extraction of
the ¢xed cells with low concentrations of Triton X-
100. Although the binding sites have not been eluci-
dated, a glycolipid binding site is suggested [42].
7. Collectin-mediated alterations in leukocyte function
7.1. Chemotaxis/haptotaxis
Natural and recombinant rat SP-D and human
proteinosis SP-D are potent chemoattractant and
haptotactic agents (maximal chemotactic response
at 5 ng/ml or V10311 M) for both monocytes and
neutrophils [10,37]. This e¡ect may be mediated by
attachment of the CRD to phagocyte surface carbo-
hydrate structures, because it is inhibited by compet-
ing saccharides and by antibodies directed against
the SP-D CRD [10]. Furthermore, trimeric human
SP-D CRDs are still very potent (V10310 M) (R.
Senior and W. Longmore, unpublished data). Inter-
estingly, SP-D concentrations su⁄cient to cause che-
motaxis were not associated with enhanced oxidative
metabolism or phagocytic activity. These results sug-
gest that carbohydrate binding properties of SP-D
result in distinctive interactions with phagocytes,
and that SP-D may play an important role in recruit-
ment or retention of phagocytic cells and the modu-
lation of in£ammatory or immune responses under
certain circumstances in vivo.
7.2. Respiratory activity
Rat SP-D has been reported to directly stimulate
the respiratory burst response of alveolar macro-
phages [43]. However, we have not observed signi¢-
cant stimulation of the respiratory response of
human neutrophils or peripheral blood monocytes
by recombinant rat or human SP-D in the absence
of a ligand or contaminating endotoxin [10,29]. The
state of protein aggregation, method of puri¢cation,
and various assay conditions may be important var-
iables.
7.3. Opsonization
There is abundant evidence that lung collectins can
bind to microorganisms and enhance their associa-
tion with leukocytes, and in a few recent studies en-
hanced internalization and killing of speci¢c organ-
isms has been demonstrated. For example, SP-D can
opsonize and enhance the killing of an unencapsu-
lated strain of K. pneumoniae by adherent macro-
phages (Itzhak Ofek, in preparation).
7.4. Non-opsonic enhancement of phagocytosis
There is also some evidence that SP-D can increase
the internalization (and sometimes the killing) of a
variety of microorganisms by modulating the func-
tion of phagocytic cells. For example, the presence of
rat or human SP-D increases the binding and inter-
nalization of E. coli by neutrophils in the presence of
calcium (Hartshorn, submitted). Signi¢cantly, inter-
nalization was also increased to some extent by pre-
incubation of the neutrophils with SP-D. As de-
scribed for IAV, the potency of various molecular
forms of SP-D correlated with the degree of subunit
multimerization. SP-D opsonized E. coli also show
enhanced binding (Hartshorn, submitted).
7.5. E¡ects on T-lymphocyte proliferation
Recombinant rat and human SP-D were found to
potently inhibit proliferation under all three condi-
tions of lymphocyte stimulation [12]. This e¡ect did
not require long range bridging interactions because
trimeric subunits of rat SP-D were more potent than
dodecamers. It is not yet known whether these e¡ects
involve direct interactions of the collectin with bind-
ing sites on the lymphocyte, or are mediated through
interactions with a subpopulation of mononuclear
phagocytes.
7.6. ‘Indirect e¡ects’ on leukocyte function
In addition to binding to and activating phago-
cytes, collectins can indirectly in£uence phagocyte
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function by altering the presentation of pathogens or
microbial ligands to the host defense cells.
7.6.1. Viral aggregation
Lectin-dependent binding aggregation of IAV by
SP-D enhances the binding of virus to neutrophils,
augments the respiratory burst response to bound
virus, enhances viral uptake, and decreases IAV-
mediated neutrophil deactivation [29]. Prior neurami-
nidase treatment of the neutrophil abrogates all of
these e¡ects, indicating that SP-D mediated viral ag-
gregation enhances the binding of virus to the natu-
ral sialic acid ‘ligands’ on the leukocyte surface. Mul-
timers of SP-D dodecamers are signi¢cantly more
e¡ective than dodecamers on a protein concentration
basis at enhancing IAV binding. Single arms and
isolated trimeric CRDs do not increase IAV binding,
and actually decrease IAV binding at relatively high
concentrations.
7.6.2. Possible e¡ects on LPS signaling pathways
SP-D has been reported to be recovered as a com-
plex with LPS in LPS-induced acute lung injury in
rats [13]. Interactions between collectins and LPS
suggest that under appropriate conditions these mol-
ecules could modulate cellular activation and signal-
ing pathways involving LPS. Such e¡ects could the-
oretically involve completion for binding by other
LPS binding proteins or altered presentation of
LPS to in£ammatory cells.
8. Tissue and airspace distribution of SP-D
Although SP-D was initially identi¢ed in lung
there is now considerable evidence for extrapulmo-
nary sites of expression. Our original immunohisto-
chemical studies suggested that in the rat SP-D is
produced in rat salivary and lacrimal gland [44].
More recently, SP-D was identi¢ed in rat gastric an-
trum [45] and murine tracheal submucosal glands
[46]. Studies by Holmskov and coworkers using
monoclonal antibodies to human SP-D demonstrated
SP-D in gastric mucosa, parotid gland, lacrimal
gland, and mammary and sweat glands (U¡e Holm-
skov, personal communication). Furthermore, re-
verse transcriptase-polymerase chain reaction assays
identi¢ed SP-D mRNA in stomach, parotid gland,
breast, and prostate. SP-D accumulates in human
and rat amniotic £uid [4,44,47]. Although most of
this material may be derived from the lung, local
synthesis by amnionic epithelial cells has not been
excluded [47].
The majority of the total immunoreactive SP-D
remains in the BAL supernatant following high
speed centrifugation (50^90% depending on the spe-
cies) [2,24]. Immunologic studies have shown that the
insoluble fraction is associated with amorphous gran-
ular material, and that the immunoreactive material
can be e⁄ciently solubilized with EDTA or speci¢c
saccharides [48]. Early studies suggested that there
was much less total SP-D than SP-A in the airspace.
However, recent comparative assays by Honda and
coworkers gave 3.1 þ 0.4 Wg/ml and 1.3 þ 0.2 Wg/ml
for SP-A and SP-D, respectively, in lavage from
healthy non-smokers [49].
Immunoreactive SP-D has also been identi¢ed in
human serum [50]. The concentration of protein in-
creases dramatically in association with idiopathic
pulmonary ¢brosis [51,52].
9. Regulation of SP-D expression
9.1. Genomic organization
Human SP-D is encoded by a single gene on chro-
mosome 10 in the region of 10q22.2^23.1 [53]. How-
ever, protein, cDNA, and genomic sequencing to-
gether suggest the existence of a number of SP-D
alleles, some of which are characterized by amino
acid substitutions in the coding region [4,53]. The
SP-D gene encodes at least one, and probably two,
untranslated exons at the 5P end of the gene, similar
to SP-A [53]. Although initial studies identi¢ed only
a single untranslated exon an additional untranslated
exon has recently been identi¢ed, the highly homol-
ogous bovine conglutinin gene contains an additional
untranslated exon [54]. A sequence virtually identical
to this exon is present in a cDNA clone of bovine
SP-D [55], and a highly homologous sequence has
been recently identi¢ed in the previously designated
¢rst intron of the human gene (Crouch and Rust,
unpublished data).
The organization of the human SP-D and SP-A
genes suggest a close evolutionary relationship. Pre-
BBADIS 61777 30-10-98
E.C. Crouch / Biochimica et Biophysica Acta 1408 (1998) 278^289 285
sumably gene duplication and exon shu¥ing events
gave rise to a primordial collagenous lectin [56,57].
Sequence comparisons suggest divergence of the
MBP and SP-D genes after divergence of a primitive
SP-A gene [58], which later diverged to give the
two SP-A genes. In the case of SP-D, insertion of
tandem duplications of an additional collagenous
cassette (117 bp) (exons 3^6) resulted in a longer
collagen domain than either SP-A or MBP [53].
Both conglutinin and CL-43 may have evolved
from SP-D [58].
9.2. Biosynthesis and cellular metabolism of SP-D
SP-D is synthesized and secreted by alveolar type
II and non-ciliated bronchiolar epithelial cells
[44,59,60]. Although there is evidence for cell-to-cell
variation in the relative production or accumulation
of SP-D by these cells in rat lung [61], populations of
these cells show similar levels of SP-D production in
vitro (Longmore and coworkers, unpublished data).
Consistent with previous studies which showed the
accumulation of SP-D in Clara cell granules, the se-
cretion of SP-D by Clara cells, but not type II cells,
is stimulated by terbutaline. Studies using human
fetal lung explants have demonstrated stimulatory
e¡ects of glucocorticoids, but showed no e¡ect of
Q-interferon, PMA, LPS, or TNF-K under conditions
leading to altered expression of SP-A [62].
9.3. Developmental regulation
The accumulation of SP-D in the rat lung in-
creases abruptly in late gestation [44,52,63]. Unlike
SP-A, SP-D mRNA and protein levels continue to
increase during the early postnatal period, and reach
their highest levels in the adult lung. The increase
during the late fetal and early post-natal period re-
£ects increased cellular expression but is also tempo-
rally correlated with increased numbers of SP-D ex-
pressing epithelial cells [64,65]. The administration of
dexamethasone in utero accelerates the appearance
of SP-D producing cells and increases the cellular
level of SP-D mRNA [63^65]. In the human, SP-D
mRNA is ¢rst detected at low levels (4^13% of adult)
in the second trimester and message levels rise stead-
ily during late fetal lung and postnatal lung develop-
ment [62]. The level of immunoreactive SP-D protein
roughly parallels the level of mRNA consistent with
predominant regulation at the level of transcription.
9.4. Alterations in SP-D production associated with
lung injury
Immunohistochemical and in situ hybridization
studies strongly suggest that the production of SP-
D is increased in association with acute injury and
epithelial activation [48,61,66]. For example, acute
hyperoxia in rats is associated with di¡erential,
time-dependent alterations in expression of SP-D
by type II and Clara cells [67].The production and
accumulation of both SP-D is increased within sev-
eral hours following intratracheal instillation of LPS
[68].
9.5. SP-D gene regulation
Sequences upstream from the start site of SP-D
transcription contain numerous potential cis-regula-
tory elements. These include a conserved canonical
AP-1 sequence, several AP-1 and CRE-like sequen-
ces, as well as sequences similar to those identi¢ed in
conglutinin and other acute phase proteins (e.g., NF-
IL6). The conserved AP-1 element at 3109 binds to
AP-1 proteins (e.g., fra-1 and junD) in H441 cell
nuclear extracts. In addition, site-directed mutagene-
sis of the consensus markedly decreases basal and
dexamethasone-stimulated promoter activity in tran-
sient transfection assays using H441 cells. Although
dexamethasone increases SP-D promoter activity
[69], these e¡ects are indirect and possibly involve
interactions of glucocorticoid receptor with other
transcription factors. SP-D appears to be encoded
by a single major transcript in adult rat and human
lung, developmental or pharmacologically induced
changes in RNA processing have not been excluded.
9.6. Cellular pathway of assembly and secretion
Recent studies of recombinant SP-D assembly by
CHO-K1 cells indicate that folding of the CRD, tri-
merization of monomers, triple helix formation, the
amino-terminal association of trimeric subunits, and
the formation of interchain disul¢de crosslinks occur
in the rough endoplasmic reticulum, and that oligo-
saccharide maturation occurs in the Golgi immedi-
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ately prior to secretion [70]. Reid and coworkers
have shown that the linking peptide (L) of bovine
SP-D and conglutinin can spontaneously form stable
trimers consistent with a trimeric coiled-coil [71].
Thus, within the context of the full length molecule
the L peptide domain may serve to register the three
polypeptide chains of SP-D prior to folding of the
collagen helix, and the subsequent formation of in-
terchain disul¢de bonds.
9.7. Degradation of SP-D
Relatively little is known about the degradation or
turnover of SP-D. SP-D is found in both endosomal
vesicles and lysosomal granules of alveolar macro-
phages indicating that these cells can also internalize
SP-D [42]. Furthermore, it has recently been shown
that alveolar macrophages rapidly degrade radiola-
beled SP-D by cell-associated proteases in vitro [72].
Interestingly, puri¢ed SP-D dodecamers are not de-
graded by elastase or a variety of secreted mamma-
lian neutral proteinases at 37‡C in the presence of
physiologic calcium concentrations [15].
10. Summary
There is growing evidence that SP-D modulates
important interactions between the host and inhaled
microorganisms and participate in aspects of pulmo-
nary immune and in£ammatory regulation. SP-D
shows calcium-dependent lectin-mediated interac-
tions with glycoconjugates expressed on a wide vari-
ety of microorganisms (and certain complex organic
particulates) in vitro. In addition, the collectins can
in£uence the activity of phagocytes through lectin-
dependent and -independent interactions. Trimeric
subunits of SP-D molecules show speci¢c and high
a⁄nity binding to various saccharide ligands. How-
ever, the oligomerization of trimeric subunits is es-
sential for agglutination and other long-range bridg-
ing interactions.
There are several biochemical di¡erences between
SP-A and SP-D that likely confer distinctive func-
tional properties in vivo. The most important of
these include: (1) di¡erences in solubility at physio-
logic ionic strength which may in£uence compart-
mentalization and availability in the airspace lining
material, (2) di¡erences in the length of the collagen
domain which determine their capacities to partici-
pate in long-range bridging interactions, (3) di¡eren-
ces in CRD speci¢city or valency, and (4) di¡erences
in the localization of Asn-linked sugars.
The distinct yet overlapping activities actions of
SP-A and SP-D in vitro suggest that the proteins
may be functionally complementary in vivo. The
molecules appear to occupy di¡erent airspace com-
partments, and sometimes recognize di¡erent ligands
or ligand domains. The biologic importance of bind-
ing to surfactant lipids is unknown, however these
interactions could primarily serve to orient the mol-
ecules in relation to the alveolar lining material or to
modify the presentation of other bound materials to
pulmonary cells.
The possibility that acquired or genetically deter-
mined di¡erences in SP-D activity may in part ac-
count for di¡erences in the susceptibility of individ-
uals to microbial challenge, particularly in the setting
of inadequate or impaired speci¢c immunity, or con-
tribute to the pathogenesis of certain immunologi-
cally mediated lung disorders, such as allergic asth-
ma, requires further investigation.
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